Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression,
β¦ LIBER β¦
Immunotherapy of cancer
β Scribed by Franco M. Muggia
- Publisher
- Springer-Verlag
- Year
- 1977
- Tongue
- English
- Weight
- 464 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Immunotherapy of bladder cancer
β
Unyime O. Nseyo; Donald L. Lamm
π
Article
π
1997
π
John Wiley and Sons
π
English
β 48 KB
π 2 views
Immunotherapy of cancerβIntroduction
β
Yosef H. Pilch
π
Article
π
1977
π
Springer
π
English
β 218 KB
Immunotherapy for cancer
β
P. J. Guillou
π
Article
π
1991
π
John Wiley and Sons
π
English
β 188 KB
Specific cancer immunotherapy
β
Morton D. Prager
π
Article
π
1978
π
Springer-Verlag
π
English
β 588 KB
Immunotherapy of metastatic kidney cance
β
Giancarlo Pizza; Caterina De Vinci; Giuseppe Lo Conte; Paolo Maver; Ennio Dragon
π
Article
π
2001
π
John Wiley and Sons
π
French
β 337 KB
122 MRCC patients were treated by monthly intralymphatic injections (containing a mean of 573 IL-2 U and 26 Ψ 10 6 LAK cells) and i.m. administration of IFN and TF; 71 patients also received a 3-day cycle of monthly IL-2 inhalations with a mean of 998 daily U. MRCC cases not treated by immunotherapy
Non-antibody immunotherapy of cancer
β
Paul B. Chapman; Alan N. Houghton
π
Article
π
1993
π
Elsevier Science
π
English
β 704 KB